Bezlotoxumab (Zinplava)

Covered only as a single IV dose (up to 10 mg/kg) of bezlotoxumab to reduce recurrence of C. difficile infection in patients currently receiving antibacterial therapy and at high risk for recurrence; prior receipt of bezlotoxumab is excluded. Approval requires documentation of CDI diagnosis, active antibacterial treatment, justification of high‑risk status, confirmation of no prior bezlotoxumab, patient weight, and an administration/ dosing record; approval limited to one dose.

"To reduce the recurrence of Clostridium difficile infection (CDI) in individuals who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence."

Sign up to see full coverage criteria, indications, and limitations.